MX2023004554A - Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. - Google Patents
Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.Info
- Publication number
- MX2023004554A MX2023004554A MX2023004554A MX2023004554A MX2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A
- Authority
- MX
- Mexico
- Prior art keywords
- psilocybin
- benzodiazepines
- regimen
- following
- increase sensitivity
- Prior art date
Links
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 title abstract 3
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 title abstract 3
- 229940049706 benzodiazepine Drugs 0.000 title abstract 2
- 150000001557 benzodiazepines Chemical class 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La descripción proporciona métodos para tratar a un paciente que lo necesite, que comprenden la administración conjunta al paciente de una dosis terapéuticamente eficaz de psilocibina y una o más benzodiazepinas. La presente descripción también proporciona métodos para reducir el período de descanso con ISRS en pacientes antes de la administración de la terapia con psilocibina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094624P | 2020-10-21 | 2020-10-21 | |
| PCT/EP2021/079287 WO2022084480A1 (en) | 2020-10-21 | 2021-10-21 | Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004554A true MX2023004554A (es) | 2023-05-08 |
Family
ID=78414638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004554A MX2023004554A (es) | 2020-10-21 | 2021-10-21 | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4232047A1 (es) |
| JP (1) | JP2023546238A (es) |
| KR (1) | KR20230096003A (es) |
| CN (1) | CN116940362A (es) |
| AU (1) | AU2021363627A1 (es) |
| CA (1) | CA3193308A1 (es) |
| GB (1) | GB2615708A (es) |
| IL (1) | IL302258A (es) |
| MX (1) | MX2023004554A (es) |
| WO (1) | WO2022084480A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020358720A1 (en) | 2019-10-01 | 2022-04-21 | Empyrean Neuroscience, Inc. | Genetic engineering of fungi to modulate tryptamine expression |
| WO2023130078A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified mycelium for producing psychotropic alkaloids |
| US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
| WO2023220367A1 (en) * | 2022-05-13 | 2023-11-16 | Reset Pharmaceuticals, Inc. | Administration of a psychedelic compound by intramuscular injection |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3955936A1 (en) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
-
2021
- 2021-10-21 AU AU2021363627A patent/AU2021363627A1/en active Pending
- 2021-10-21 CN CN202180079121.8A patent/CN116940362A/zh active Pending
- 2021-10-21 GB GB2307291.1A patent/GB2615708A/en active Pending
- 2021-10-21 EP EP21799216.3A patent/EP4232047A1/en active Pending
- 2021-10-21 IL IL302258A patent/IL302258A/en unknown
- 2021-10-21 CA CA3193308A patent/CA3193308A1/en active Pending
- 2021-10-21 KR KR1020237016975A patent/KR20230096003A/ko active Search and Examination
- 2021-10-21 WO PCT/EP2021/079287 patent/WO2022084480A1/en active Application Filing
- 2021-10-21 MX MX2023004554A patent/MX2023004554A/es unknown
- 2021-10-21 JP JP2023524348A patent/JP2023546238A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3193308A1 (en) | 2022-04-28 |
| WO2022084480A1 (en) | 2022-04-28 |
| EP4232047A1 (en) | 2023-08-30 |
| KR20230096003A (ko) | 2023-06-29 |
| GB2615708A (en) | 2023-08-16 |
| IL302258A (en) | 2023-06-01 |
| CN116940362A (zh) | 2023-10-24 |
| JP2023546238A (ja) | 2023-11-01 |
| GB202307291D0 (en) | 2023-06-28 |
| AU2021363627A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004554A (es) | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. | |
| MX2021002886A (es) | Terapia de combinacion para el tratamiento de cancer de mama triple negativo. | |
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| MX2019010733A (es) | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| Zhu et al. | Acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy | |
| MX2021005992A (es) | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. | |
| MX2021011110A (es) | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. | |
| MX2021009051A (es) | Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| Razzaghdoust et al. | Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy | |
| PH12020551726A1 (en) | Treatment of atopic dermatitis | |
| CL2018002734A1 (es) | Métodos de tratamiento con vitamina d | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| Jordan et al. | Trabectedin: Supportive care strategies and safety profile | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| Bali et al. | Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2024005632A (es) | Tratamiento de la depresion resistente al tratamiento con psilocibina. | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| MX2024001892A (es) | Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos. | |
| CN105380956A (zh) | 一种治疗白血病的含艾德拉尼的药物组合物及应用 |